Stryker Corporation (NYSE:SYK) – Equities research analysts at Gabelli decreased their FY2018 earnings per share (EPS) estimates for Stryker Corporation in a research report issued to clients and investors on Monday. Gabelli analyst J. Tsai now forecasts that the medical technology company will post earnings per share of $7.10 for the year, down from their previous forecast of $7.15. Gabelli also issued estimates for Stryker Corporation’s FY2019 earnings at $7.80 EPS and FY2021 earnings at $9.50 EPS.

Several other equities research analysts have also issued reports on the stock. Oppenheimer Holdings, Inc. set a $156.00 price target on shares of Stryker Corporation and gave the company a “hold” rating in a report on Monday. Cowen and Company set a $166.00 price target on shares of Stryker Corporation and gave the company a “buy” rating in a report on Sunday. Barclays PLC lifted their price target on shares of Stryker Corporation from $137.00 to $148.00 and gave the company an “underweight” rating in a report on Friday. Canaccord Genuity lifted their price target on shares of Stryker Corporation from $155.00 to $162.00 and gave the company a “buy” rating in a report on Friday. Finally, Stifel Nicolaus lifted their price target on shares of Stryker Corporation from $158.00 to $168.00 and gave the company a “buy” rating in a report on Friday. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $151.52.

TRADEMARK VIOLATION NOTICE: “Brokers Issue Forecasts for Stryker Corporation’s FY2018 Earnings (SYK)” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/31/brokers-issue-forecasts-for-stryker-corporations-fy2018-earnings-syk.html.

Shares of Stryker Corporation (SYK) traded down 0.08% during trading on Tuesday, hitting $155.24. 730,015 shares of the stock were exchanged. The firm has a 50 day moving average price of $145.94 and a 200 day moving average price of $142.17. The firm has a market capitalization of $58.07 billion, a P/E ratio of 34.65 and a beta of 0.81. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $160.62.

Stryker Corporation (NYSE:SYK) last announced its earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.02. Stryker Corporation had a net margin of 14.67% and a return on equity of 24.11%. The company had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same period in the prior year, the business earned $1.39 earnings per share. Stryker Corporation’s quarterly revenue was up 6.1% on a year-over-year basis.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be given a $0.425 dividend. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.09%. Stryker Corporation’s dividend payout ratio (DPR) is currently 36.32%.

In related news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the transaction, the insider now owns 88,207 shares in the company, valued at approximately $12,909,976.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Graham A. Mclean sold 1,124 shares of the business’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the transaction, the insider now owns 8,983 shares in the company, valued at approximately $1,313,853.58. The disclosure for this sale can be found here. 7.40% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in SYK. Acrospire Investment Management LLC bought a new stake in Stryker Corporation during the 2nd quarter valued at $111,000. Bollard Group LLC increased its stake in Stryker Corporation by 0.4% during the 2nd quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 3 shares in the last quarter. Motco increased its stake in Stryker Corporation by 50.7% during the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 278 shares in the last quarter. Bruderman Asset Management LLC bought a new stake in Stryker Corporation during the 2nd quarter valued at $150,000. Finally, James Investment Research Inc. bought a new stake in Stryker Corporation during the 2nd quarter valued at $155,000. Institutional investors own 74.00% of the company’s stock.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Earnings History and Estimates for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.